MetaCap

Mirum Pharmaceuticals Inc. (MIRM)

NASDAQ: MIRMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

96.13+0.62 (+0.65%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

MIRM stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$14.47
52-week range
63.23 – 130.00
Day range
94.10 – 98.39
Volume / Avg
1.06M / 692.51K
Beta
—

52-week range

$63.23$130.00

MIRM stock today

Mirum Pharmaceuticals (MIRM) closed at $96.13 on Nov 20, up 0.65% (+$0.62), versus the S&P 500's 3.70% decline. Shares are 26.1% below their 52-week high of $130.00, set on Jul 9, 2026 and 52.0% above the 52-week low of $63.23, in the middle of the past year's range. MIRM is up 21.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 35.5%.

Mirum Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$14.47), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Mirum Pharmaceuticals

Company profile

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Christopher Peetz
Headquarters
Foster City, CA
Employees
470
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, Mirum Pharmaceuticals generated $521.3 million in revenue, up 54.7% from fiscal 2024, its 5th consecutive year of revenue growth. Mirum Pharmaceuticals reported a net loss of $23.4 million, compared with a loss of $87.9 million a year earlier. Operating margin was -4.2%.

Mirum Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$521.31M$336.89M$186.37M$77.06M$19.14M
Growth+54.74%+80.76%+141.85%+302.66%—
Net income$-23.36M$-87.94M$-163.41M$-135.66M$-83.99M
EPS (diluted)$-0.47$-1.85$-4.00$-4.02$-2.77

Analyst forecast

Forecast

Consensus (12 analysts)

strong_buy

Avg. price target

$157.71+64.06%

  • Strong buy 4
  • Buy 8
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $118.00High $202.28

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-0.87 vs $-0.53
Surprise
-64.15%

MIRM news

All MIRM news

Mirum Pharmaceuticals peers

Health Care sector
MIRM peer companies
CompanyPrice% ChgMarket capCompare
ABVXAbivax SA ADR73.20-9.24%$6.41Bvs MIRM
SUPNSupernus Inc.28.61+0.92%$5.94Bvs MIRM
ARWRArrowhead Pharmaceuticals Inc.41.37-5.22%$5.85Bvs MIRM
LGNDLigand Pharmaceuticals Incorporated286.85-0.03%$5.74Bvs MIRM
AXSMAxsome Therapeutics Inc.129.36-4.66%$6.80Bvs MIRM
GRFSGrifols S.A. ADR8.15-0.61%$5.55Bvs MIRM
CORTCorcept Therapeutics Incorporated63.62-2.09%$6.96Bvs MIRM
CYTKCytokinetics Incorporated50.78-1.32%$7.07Bvs MIRM

Indexes, lists and sector

Mirum Pharmaceuticals stock FAQ

What is Mirum Pharmaceuticals's stock price today?

MIRM last traded at $96.13 as of Nov 20, 4:00 PM EST, up 0.65% on the day. Prices are delayed at least 15 minutes.

Who is Mirum Pharmaceuticals's CEO?

Mr. Christopher Peetz is the chief executive officer of Mirum Pharmaceuticals Inc., which has about 470 employees.

What is the MIRM 52-week high?

The 52-week high for MIRM is $130.00 and the 52-week low is $63.23. The stock is currently 26.1% below its high.

Compare MIRM